Pharma


  • A worker prepares ampoules of the Nuvaxovid vaccine against Covid-19 by Novavax in Berlin, Germany in February 2022.
    Image attribution tooltip
    Carsten Koall via Getty Images

    Novavax slashes revenue forecasts amid slow demand for COVID-19 vaccine

    The biotech now expects about $2 billion in revenue in 2022, less than half its previous estimates, after sales fell sharply in the second quarter.

    By Aug. 9, 2022
  • Image attribution tooltip
    Mario Tama via Getty Images

    J&J’s head of R&D departs as pharma’s leadership turns over

    Mathai Mammen is leaving to “pursue other opportunities,” J&J said in an abrupt announcement. William Hait, currently head of external innovation, will take Mammen’s place in the interim.

    By Aug. 9, 2022
  • Trendline

    The expanding world of RNA therapies

    Vaccines from BioNTech and Moderna proved the power of messenger RNA in medicine. A growing field of RNA-targeting therapies is advancing alongside them.

    By BioPharma Dive staff
  • A building framed through tree foliage is seen with a sign that reads "Lilly."
    Image attribution tooltip

    Kris Tripplaar/Sipa/Newscom

    Lilly criticizes Indiana abortion law, indicating it may look elsewhere to hire

    After Indiana’s governor signed a near-total abortion ban into law, the drugmaker said it will rethink future hiring in the state.

    By Aug. 8, 2022
  • A sign for Pfizer is seen outside the Pfizer headquarters on November 9, 2020 in New York City.
    Image attribution tooltip
    David Dee Delgado via Getty Images

    Pfizer buys sickle cell drugmaker Global Blood for $5.4B

    The acquisition gives Pfizer access to Oxbryta, an approved drug for the blood condition, as well as two experimental medicines.

    By , Updated Aug. 8, 2022
  • A logo of Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences

    How a small UK biotech ended up in Gilead’s hands

    MiroBio, which was spun out of the University of Oxford three years ago, drew Gilead’s interest with its autoimmune disease research.

    By Aug. 5, 2022
  • Image attribution tooltip
    Novo Nordisk

    Novo shares tumble after latest setbacks for closely watched obesity drug

    The Danish drugmaker lost tens of billions in market value after revealing a key clinical study for Wegovy won't be stopped early and production issues are still being ironed out.

    By Kristin Jensen • Aug. 4, 2022
  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images

    With new data, Roche takes step toward more convenient cancer immunotherapy

    The pharma claimed Phase 3 study success for a subcutaneous version of its drug Tecentriq, a strategy it and rivals Merck and Bristol Myers could use to extend the market life of their lucrative drugs.

    By Aug. 2, 2022
  • Confident mid adult female scientists work together in a laboratory.
    Image attribution tooltip
    SDI Productions via Getty Images
    Sponsored by Avanir Pharmaceuticals

    The cost of purpose: Finding personal fulfillment in a pharmaceutical career

    Wa’el Hashad, President and CEO of Avanir Pharmaceuticals, discusses purpose and fulfillment in a pharmaceutical career.

    By Wa’el Hashad, President and CEO, Avanir Pharmaceuticals • Aug. 1, 2022
  • A general view of AstraZeneca is seen during Prime Minister Scott Morrison's visit on August 19, 2020 in Sydney, Australia.
    Image attribution tooltip
    Lisa Maree Williams via Getty Images

    AbbVie cancer drug sales fall as AstraZeneca competitor gains ground

    Imbruvica, long one of AbbVie’s top-selling medicines, has ceded market share in treating chronic lymphocytic leukemia to AstraZeneca’s Calquence.

    By July 29, 2022
  • Image attribution tooltip
    Dan Kitwood via Getty Images

    Pfizer sales of COVID-19 vaccine, pill beat forecasts as company prepares for future waves

    The company plans to ready a booster shot by the fall that targets the BA.4 and BA.5 strains that are currently most prevalent in the U.S. and other countries.

    By Updated July 28, 2022
  • Image attribution tooltip
    Novartis

    Novartis asks FDA to approve biosimilar for Biogen’s top-selling MS drug

    Biogen will try to enforce patents protecting Tysabri, but an executive last week acknowledged that copycat drugs could launch when approved in the U.S.

    By July 25, 2022
  • The World Health Organization emblem of a snake symbol for medicine coiling around UN symbol.
    Image attribution tooltip
    Sean Gallup via Getty Images

    EU speeds approval of monkeypox vaccine as WHO declares public health emergency

    Vaccine maker Bavarian Nordic said it is meeting demand for its shot with production capacity of 30 million doses a year.

    By July 25, 2022
  • Image attribution tooltip
    Carl Court via Getty Images

    European regulator recommends Bavarian Nordic's vaccine for monkeypox

    The positive decision comes as governments aim to expand supply and quicken distribution of the vaccine to combat a widening global outbreak. Separately, the EMA backed approvals of 11 other medicines.

    By July 22, 2022
  • Roche CEO Severin Schwan
    Image attribution tooltip
    Courtesy of Roche

    Roche CEO Schwan, who guided company as cancer drug powerhouse, to step down next year

    The drugmaker’s current diagnostics chief Thomas Schinecker will take over as CEO in March, while Schwan will seek election as chair of Roche’s board.

    By July 21, 2022
  • Rendered illustration of human DNA
    Image attribution tooltip
    DKosig via Getty Images

    Roche digs deeper into gene therapy for the eye

    The Swiss drugmaker, which already owns rights to a marketed gene therapy for inherited vision loss, will work with startup Avista Therapeutics to develop better delivery tools for the complex treatments. 

    By July 20, 2022
  • Image attribution tooltip
    Jacob Bell / BioPharma Dive

    Merck terminates Lynparza trial in colorectal cancer

    The setback slows plans to broaden use of a drug that analysts expect to generate nearly $10 billion in annual sales later this decade.  

    By July 19, 2022
  • Image attribution tooltip
    Novartis

    Novartis forecasts improving generic drug business as it weighs unit's future

    The pharmaceutical company is considering selling or splitting off its struggling Sandoz division and expects to give an update by the end of the year.

    By July 19, 2022
  • Image attribution tooltip
    Brian Tucker / BioPharma Dive

    Drug deals, launches in focus as pharma earnings begin

    Second quarter reports could bring questions on a reportedly forthcoming $40 billion takeover, GSK’s new slimmed-down look and market uptake for expected blockbusters from Lilly and Bristol Myers.

    By , July 18, 2022
  • A worker prepares ampoules of the Nuvaxovid vaccine against Covid-19 by Novavax in Berlin, Germany in February 2022.
    Image attribution tooltip
    Carsten Koall via Getty Images

    EMA adds allergic reaction warning to Novavax's COVID-19 vaccine

    The regulator said there have been “a few” spontaneous severe allergic reactions following administration of the vaccine, which was this week authorized in the U.S.

    By July 15, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    Novartis, BeiGene cancer drug faces delay as FDA puts off approval decision

    The deferral puts the drug in regulatory limbo, setting back the Swiss pharma's efforts to catch up to top immunotherapy developers Merck, Bristol Myers Squibb and Roche.

    By July 14, 2022
  • A worker prepares ampoules of the Nuvaxovid vaccine against Covid-19 by Novavax in Berlin, Germany in February 2022.
    Image attribution tooltip
    Carsten Koall via Getty Images

    FDA clears Novavax's COVID-19 vaccine as 4th option in US

    The shot is the first of its type authorized for COVID-19 by the FDA, but faces an uncertain future due to questions about its ability to fight omicron as well as the biotech’s ability to manufacture large quantities. 

    By Updated July 13, 2022
  • A Merck & Co. sign sits in front of a Georgia facility July 9, 2002 in Duluth, Georgia.
    Image attribution tooltip
    Erik S. Lesser via Getty Images

    Merck wagers $290M on a cancer treatment from Finnish drugmaker

    The treatment, developed by Orion Corporation, is in Phase 2 testing for advanced prostate cancer, and adds to Merck’s oncology pipeline

    By Kristin Jensen • July 13, 2022
  • Colonies of bacteria in MacConkey agar
    Image attribution tooltip
    Md Saiful Islam Khan via Getty Images

    Healthcare asset manager Innoviva buys another biotech at a bargain price

    Two months after acquiring Entasis Therapeutics, the firm reached a deal to buy La Jolla Pharmaceutical Co. at a fraction of what La Jolla was worth just a few years ago.

    By July 11, 2022
  • A female doctor bend's down to eye level as she talks with a cancer patient who is receiving her treatment intravenously. She is wearing a white lab coat and has a clipboard in hand as she takes notes
    Image attribution tooltip
    FatCamera via Getty Images
    Sponsored by Worldwide Clinical Trials

    De-risking oncology trials with medical monitoring

    Phase three oncology studies have approximately a 35% likelihood of leading to regulatory approval.

    July 11, 2022
  • Beta-Amyloid Plaques and Tau in the Brain
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.

    AbbVie dials back partnership on experimental Alzheimer's drug

    While AbbVie is bailing on one of the two programs it paid Alector $205 million to acquire five years ago, work will continue on the second project. That drug, however, has shown safety signals.  

    By July 8, 2022